Adapthealth Corp.: what the price is pricing in
The price implies cash-flow growth of 3.2% a year; our model expects 2.9%. The gap is too narrow for a position this quarter. Switch lens below to see the same question asked of earnings, growth, sales and book value.
No published rating for Adapthealth Corp.: data-quality checks not passed. The readings below run our models backwards for research and show how trading the gap would have done; they are not a valuation or a rating. The valuation page shows the models and their status.
What growth in cash flow is the price paying for?
The price implies cash-flow growth of 3.2% a year; our model expects 2.9%.
Gap too narrow for a position this quarter
Over time
$10,000 trading the gap vs the S&P 500
Skill or luck?
In plain English: With only 1 quarters of positions, Adapthealth Corp.'s own record is too short to tell skill from luck. The results across all companies on the priced-in page are the better guide.
| Positions | Quarters | Beat the S&P 500 | Average vs S&P 500, a quarter | Typical (median), a quarter | A year | Confidence (t) | Evidence |
|---|---|---|---|---|---|---|---|
| Longs | 1 | 0.0% | −42.8% | −42.8% | −89.3% | — | Too few quarters |
| Shorts | 0 | — | — | — | — | — | — |
| All positions | 1 | 0.0% | −42.8% | −42.8% | −89.3% | — | Too few quarters |
Every quarter (23)
| From | Price paid | Growth the price implies | Growth our model assumes | Position | AHCO | S&P 500 |
|---|---|---|---|---|---|---|
| September 30, 2026 (open) | $5.64 | 3.2% | 2.9% | No position | +4.8% | −0.8% |
| June 30, 2026 | $10.42 | 6.4% | 2.0% | No position | −45.9% | +2.4% |
| March 31, 2026 | $11.90 | 3.8% | 2.0% | No position | −12.4% | +15.1% |
| December 31, 2025 | $9.96 | 7.3% | 2.0% | No position | +19.5% | −4.4% |
| September 30, 2025 | $8.95 | -1.3% | 2.0% | No position | +11.3% | +2.7% |
| June 30, 2025 | $9.43 | 0.7% | 3.3% | No position | −5.1% | +8.1% |
| March 31, 2025 | $10.84 | 2.0% | 5.9% | No position | −13.0% | +10.8% |
| December 31, 2024 | $9.52 | 2.1% | 10.2% | No position | +13.9% | −4.3% |
| September 30, 2024 | $11.23 | 8.0% | 10.4% | No position | −15.2% | +2.5% |
| June 30, 2024 | $10.00 | 9.1% | 13.0% | No position | +12.3% | +5.8% |
| March 31, 2024 | $11.51 | 9.0% | 13.0% | No position | −13.1% | +4.4% |
| December 31, 2023 | $7.29 | 8.2% | 13.0% | No position | +57.9% | +10.4% |
| September 30, 2023 | $9.10 | 9.7% | 13.0% | No position | −19.9% | +11.6% |
| June 30, 2023 | $12.17 | 7.5% | 13.0% | No position | −25.2% | −3.2% |
| March 31, 2023 | $12.43 | 9.5% | 13.0% | No position | −2.1% | +8.7% |
| December 31, 2022 | $19.22 | 9.4% | 20.0% | Long | −35.3% | +7.5% |
| September 30, 2022 | $18.78 | 8.2% | 13.0% | No position | +2.3% | +7.6% |
| June 30, 2022 | $18.04 | 7.7% | 13.0% | No position | +4.1% | −4.9% |
| March 31, 2022 | $16.03 | 5.5% | 13.0% | No position | +12.5% | −16.1% |
| December 31, 2021 | $24.46 | 7.8% | 13.0% | No position | −34.5% | −4.6% |
| September 30, 2021 | $23.29 | 7.0% | 13.0% | No position | +5.0% | +11.1% |
| June 30, 2021 | $27.41 | 9.4% | 13.0% | No position | −15.0% | +0.6% |
| March 31, 2021 | $36.76 | 3.7% | 13.0% | No position | −25.4% | +8.4% |
What growth in earnings is the price paying for?
No current reading. The latest is from December 31, 2025: the figures this lens needs have not been filed recently enough (or no longer apply), so there is no position this quarter.
Over time
$10,000 trading the gap vs the S&P 500
Skill or luck?
In plain English: With only 3 quarters of positions, Adapthealth Corp.'s own record is too short to tell skill from luck. The results across all companies on the priced-in page are the better guide.
| Positions | Quarters | Beat the S&P 500 | Average vs S&P 500, a quarter | Typical (median), a quarter | A year | Confidence (t) | Evidence |
|---|---|---|---|---|---|---|---|
| Longs | 2 | 100.0% | +18.8% | +18.8% | +96.7% | — | Too few quarters |
| Shorts | 1 | 100.0% | +29.9% | +29.9% | +184.3% | — | Too few quarters |
| All positions | 3 | 100.0% | +22.5% | +28.6% | +122.4% | 3.34 | Too few quarters |
Every quarter (12)
| From | Price paid | Growth the P/E implies | Growth our model assumes | Position | AHCO | S&P 500 |
|---|---|---|---|---|---|---|
| December 31, 2025 | $9.96 | 1.0% | 2.0% | No position | +19.5% | −4.4% |
| September 30, 2025 | $8.95 | -0.5% | 2.0% | No position | +11.3% | +2.7% |
| June 30, 2025 | $9.43 | -0.6% | 3.3% | No position | −5.1% | +8.1% |
| March 31, 2025 | $10.84 | 0.4% | 5.9% | No position | −13.0% | +10.8% |
| September 30, 2023 | $9.10 | 11.0% | 13.0% | No position | −19.9% | +11.6% |
| June 30, 2023 | $12.17 | 15.7% | 13.0% | No position | −25.2% | −3.2% |
| March 31, 2023 | $12.43 | 9.2% | 13.0% | No position | −2.1% | +8.7% |
| December 31, 2022 | $19.22 | 10.4% | 20.0% | No position | −35.3% | +7.5% |
| September 30, 2022 | $18.78 | 3.4% | 13.0% | No position | +2.3% | +7.6% |
| June 30, 2022 | $18.04 | -3.9% | 13.0% | Long | +4.1% | −4.9% |
| March 31, 2022 | $16.03 | -1.8% | 13.0% | Long | +12.5% | −16.1% |
| December 31, 2021 | $24.46 | 24.9% | 13.0% | Short | −34.5% | −4.6% |
What profit margin is the price paying for?
The price implies an owner-earnings margin of 4.6%; the company has kept 4.6%.
Gap too narrow for a position this quarter
Over time
$10,000 trading the gap vs the S&P 500
Skill or luck?
In plain English: With only 1 quarters of positions, Adapthealth Corp.'s own record is too short to tell skill from luck. The results across all companies on the priced-in page are the better guide.
| Positions | Quarters | Beat the S&P 500 | Average vs S&P 500, a quarter | Typical (median), a quarter | A year | Confidence (t) | Evidence |
|---|---|---|---|---|---|---|---|
| Longs | 1 | 0.0% | −33.8% | −33.8% | −80.8% | — | Too few quarters |
| Shorts | 0 | — | — | — | — | — | — |
| All positions | 1 | 0.0% | −33.8% | −33.8% | −80.8% | — | Too few quarters |
Every quarter (23)
| From | Price paid | Margin the price implies | Margin delivered | Position | AHCO | S&P 500 |
|---|---|---|---|---|---|---|
| September 30, 2026 (open) | $5.64 | 4.6% | 4.6% | No position | +4.8% | −0.8% |
| June 30, 2026 | $10.42 | 6.1% | 4.8% | No position | −45.9% | +2.4% |
| March 31, 2026 | $11.90 | 6.3% | 5.6% | No position | −12.4% | +15.1% |
| December 31, 2025 | $9.96 | 5.9% | 4.3% | No position | +19.5% | −4.4% |
| September 30, 2025 | $8.95 | 5.8% | 7.0% | No position | +11.3% | +2.7% |
| June 30, 2025 | $9.43 | 5.5% | 6.4% | No position | −5.1% | +8.1% |
| March 31, 2025 | $10.84 | 5.0% | 6.3% | No position | −13.0% | +10.8% |
| December 31, 2024 | $9.52 | 3.8% | 6.0% | No position | +13.9% | −4.3% |
| September 30, 2024 | $11.23 | 4.1% | 4.7% | No position | −15.2% | +2.5% |
| June 30, 2024 | $10.00 | 3.4% | 4.3% | No position | +12.3% | +5.8% |
| March 31, 2024 | $11.51 | 3.6% | 4.5% | No position | −13.1% | +4.4% |
| December 31, 2023 | $7.29 | 3.2% | 4.2% | No position | +57.9% | +10.4% |
| September 30, 2023 | $9.10 | 3.5% | 4.3% | No position | −19.9% | +11.6% |
| June 30, 2023 | $12.17 | 4.0% | 5.5% | No position | −25.2% | −3.2% |
| March 31, 2023 | $12.43 | 4.3% | 5.2% | No position | −2.1% | +8.7% |
| December 31, 2022 | $19.22 | 3.6% | 6.5% | No position | −35.3% | +7.5% |
| September 30, 2022 | $18.78 | 5.4% | 7.0% | No position | +2.3% | +7.6% |
| June 30, 2022 | $18.04 | 5.5% | 7.4% | No position | +4.1% | −4.9% |
| March 31, 2022 | $16.03 | 5.7% | 8.7% | No position | +12.5% | −16.1% |
| December 31, 2021 | $24.46 | 8.2% | 11.0% | No position | −34.5% | −4.6% |
| September 30, 2021 | $23.29 | 9.1% | 12.8% | No position | +5.0% | +11.1% |
| June 30, 2021 | $27.41 | 11.6% | 14.2% | No position | −15.0% | +0.6% |
| March 31, 2021 | $36.76 | 9.2% | 15.5% | Long | −25.4% | +8.4% |
What return on equity is the price paying for?
The price implies a return on equity of 5.8%; the company earned -15.4%.
Market more optimistic than our model: short this quarter
Over time
$10,000 trading the gap vs the S&P 500
Skill or luck?
In plain English: Across 13 quarters with a position, this lens beat the S&P 500 in 10, by +14.5% a quarter on average. That stands out clearly from chance. One company is a small sample: the results across all companies are the better guide.
| Positions | Quarters | Beat the S&P 500 | Average vs S&P 500, a quarter | Typical (median), a quarter | A year | Confidence (t) | Evidence |
|---|---|---|---|---|---|---|---|
| Longs | 0 | — | — | — | — | — | — |
| Shorts | 13 | 76.9% | +14.5% | +17.7% | +52.0% | 2.00 | Strong evidence |
| All positions | 13 | 76.9% | +14.5% | +17.7% | +52.0% | 2.00 | Strong evidence |
Every quarter (23)
| From | Price paid | Return on equity the price implies | Return on equity delivered | Position | AHCO | S&P 500 |
|---|---|---|---|---|---|---|
| September 30, 2026 (open) | $5.64 | 5.8% | -15.4% | Short | +4.8% | −0.8% |
| June 30, 2026 | $10.42 | 8.1% | -5.2% | Short | −45.9% | +2.4% |
| March 31, 2026 | $11.90 | 8.7% | -4.6% | Short | −12.4% | +15.1% |
| December 31, 2025 | $9.96 | 7.6% | 5.3% | No position | +19.5% | −4.4% |
| September 30, 2025 | $8.95 | 7.1% | 5.2% | No position | +11.3% | +2.7% |
| June 30, 2025 | $9.43 | 7.4% | 5.6% | No position | −5.1% | +8.1% |
| March 31, 2025 | $10.84 | 8.2% | 6.0% | No position | −13.0% | +10.8% |
| December 31, 2024 | $9.52 | 7.6% | -13.2% | Short | +13.9% | −4.3% |
| September 30, 2024 | $11.23 | 8.7% | -37.7% | Short | −15.2% | +2.5% |
| June 30, 2024 | $10.00 | 8.0% | -38.5% | Short | +12.3% | +5.8% |
| March 31, 2024 | $11.51 | 8.7% | -37.6% | Short | −13.1% | +4.4% |
| December 31, 2023 | $7.29 | 5.9% | -22.0% | Short | +57.9% | +10.4% |
| September 30, 2023 | $9.10 | 5.9% | 2.0% | No position | −19.9% | +11.6% |
| June 30, 2023 | $12.17 | 7.1% | 2.0% | Short | −25.2% | −3.2% |
| March 31, 2023 | $12.43 | 7.5% | 3.3% | No position | −2.1% | +8.7% |
| December 31, 2022 | $19.22 | 9.9% | 4.6% | Short | −35.3% | +7.5% |
| September 30, 2022 | $18.78 | 9.7% | 6.8% | No position | +2.3% | +7.6% |
| June 30, 2022 | $18.04 | 9.6% | 10.3% | No position | +4.1% | −4.9% |
| March 31, 2022 | $16.03 | 9.0% | 12.9% | No position | +12.5% | −16.1% |
| December 31, 2021 | $24.46 | 12.8% | 4.5% | Short | −34.5% | −4.6% |
| September 30, 2021 | $23.29 | 12.6% | -3.0% | Short | +5.0% | +11.1% |
| June 30, 2021 | $27.41 | 13.2% | -7.3% | Short | −15.0% | +0.6% |
| March 31, 2021 | $36.76 | 41.5% | -45.5% | Short | −25.4% | +8.4% |
How the test works
At each quarter end since March 2010 we rebuild the models from Adapthealth Corp.'s quarters ending at least 90 days earlier (and no more than 200 days before that), using the figures as later filed, including any restatement, and value them at that day's close, adjusted for later share splits and spin-offs so that price and share count are on the same basis. A wide enough gap is a long or a short for one quarter (growth 10 points; margin and return on equity 5 points; a PEG under 0.75 or over 3), measured on total return against the S&P 500. The rules were set before the test. No trading or borrowing costs; today's list of companies. Not investment advice. All companies and the results across them.
Compare with peers
- AMN Healthcare Services Inc priced in
- Astrana Health, Inc. priced in
- Chemed Corp priced in
- Aveanna Healthcare Holdings, Inc. priced in
- Hims & Hers Health, Inc. priced in
Head to head: AHCO vs AMNAHCO vs ASTHAHCO vs CHE
More: Health Care Services stocks compared, Health Care sector, rankings of US companies